Can osteoclasts be excluded? (Reply)

D. Holstead Jones (), Tomoki Nakashima (), Otto H. Sanchez, Ivona Kozieradzki (), Svetlana V. Komarova, Ildiko Sarosi, Sean Morony, Evelyn Rubin, Renu Sarao (), Carlo V. Hojilla, Vukoslav Komnenovic (), Young-Yun Kong, Martin Schreiber, S. Jeffrey Dixon, Stephen M. Sims, Rama Khokha, Teiji Wada () and Josef M. Penninger ()
Additional contact information
D. Holstead Jones: *Faculty of Health Sciences, University of Ontario Institute of Technology, Oshawa, Ontario L1H 7K4, Canada
Tomoki Nakashima: Institute of Molecular Biotechnology of the Austrian Academy of Sciences
Otto H. Sanchez: Ontario Cancer Institute, University Health Network
Ivona Kozieradzki: Institute of Molecular Biotechnology of the Austrian Academy of Sciences
Svetlana V. Komarova: ‖Faculty of Dentistry, McGill University, Montreal, Quebec H3A 1A4, Canada
Ildiko Sarosi: Amgen Inc., Thousand Oaks
Sean Morony: Amgen Inc., Thousand Oaks
Evelyn Rubin: University of Toronto
Renu Sarao: Institute of Molecular Biotechnology of the Austrian Academy of Sciences
Carlo V. Hojilla: Ontario Cancer Institute, University Health Network
Vukoslav Komnenovic: Institute of Molecular Biotechnology of the Austrian Academy of Sciences
Young-Yun Kong: Pohang University of Science and Technology, Pohang
Martin Schreiber: Medical University of Vienna, Waehringer Guertel 18-20
S. Jeffrey Dixon: CIHR Group in Skeletal Development and Remodeling, Schulich School of Medicine & Dentistry, The University of Western Ontario
Stephen M. Sims: CIHR Group in Skeletal Development and Remodeling, Schulich School of Medicine & Dentistry, The University of Western Ontario
Rama Khokha: University of Toronto
Teiji Wada: Institute of Molecular Biotechnology of the Austrian Academy of Sciences
Josef M. Penninger: Institute of Molecular Biotechnology of the Austrian Academy of Sciences

Nature, 2007, vol. 445, issue 7130, E19-E20

Abstract: Abstract Martin and Mundy 1 emphasize the crucial role played by osteoclasts in the metastasis of many tumour types to bone. Our intention was not to question the importance of osteoclasts in bone metastases, but rather to show that RANK ligand (RANKL) exerts additional action on cancer cells beyond its effects on osteoclasts2. We reported that epithelial tumour cells can express RANK, a finding that is supported by earlier work3; that RANKL has chemotactic activity4; and that in vivo inhibition of RANKL by osteoprotegerin reduces tumour burden in bone when assessed in a previously published experimental system5.

Date: 2007
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature05658 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:445:y:2007:i:7130:d:10.1038_nature05658

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature05658

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().